Pharmacology: Your Learning is Never Over - PowerPoint PPT Presentation

1 / 16
About This Presentation
Title:

Pharmacology: Your Learning is Never Over

Description:

X. D2. X. D2 Receptor Interactions. No activation. Antagonist (haloperidol, etc) Partial activation ... Chinese hamster ovary D2L cells exposed to 10 mM EEDQ ... – PowerPoint PPT presentation

Number of Views:108
Avg rating:3.0/5.0
Slides: 17
Provided by: josep1
Category:

less

Transcript and Presenter's Notes

Title: Pharmacology: Your Learning is Never Over


1
Pharmacology Your Learning is Never Over
  • Joseph Awad, MD
  • February 23, 2005

2
Some Examples
  • Things are more complicated than we can imagine
  • Cilostazol (Pletal)
  • Do we really know what we need to teach ?
  • Alpha adrenergic agents
  • Finally a clinical partial agonist !
  • Aripiprazol (Abilify)
  • Moving targets
  • Lipid lowering therapy
  • Estrogen replacement

3
Test 1 Question
  • Cilostazol (Pletal) is approved by FDA (2000)
    for long-term treatment of claudication. It is a
    PDE3 inhibitor. Given what you know about other
    drugs with this mechanism of action, patients
    with which one of the following conditions should
    not get this drug.
  • Cerebrovascular disease
  • Congestive heart failure
  • Diabetes
  • Erectile dysfunction
  • Hypertension

4
Phosphodiesterase 3 Inhibitors
  • Inamrinone (formerly amrinone) and Milrinone are
    PDE3 inhibitors with inotropic effect and some
    vasodilation.
  • Long-term use of such drugs increases mortality
    in heart failure.
  • CHF patients excluded from cilostazol clinical
    trials
  • How about the real world?
  • NO!!
  • Is there a danger?
  • Is cilostazol different?

5
Cilastazol is Different
  • Cilastazol is a less potent PDE3A inhibitor than
    milrinone
  • Cilastazol also blocks uptake of adenosine into
    cardiac and other cells.
  • Makes cilastazol like an adenosine agonist
  • Additional Effects
  • Reduces inotropic influence on heart
  • More vasodilation
  • Anti-platelet activity
  • Other effects dec. TG and inc. HDL

6
Things are more Complicated
  • This drug has another MOA
  • We often dont know everything about a drug
    actions, even many years later.
  • Many drugs have more than one MOA and may not be
    like other members of the class
  • Vasodilatory effects marketed in this country
  • Anti-platelet effects underplayed
  • We still dont have hard data on long-term safety
    in CHF patients ! ! !
  • Keep an Open Mind

7
What to Teach ?
  • A decade ago
  • Alpha 1 blockers dead as antihypertensives
  • Tachyphylaxis, trigger baroreflex sympathetic
    output
  • Alpha 2 agonists dead as antihypertensives
  • Too sedating, too many side effects, clonidine
    rebound
  • Phentolamine and Phenoxybenzamine
  • How many pheos am I ever going to see ?
  • 15 minutes, max !
  • Ephedra and phenylpropanolamine banned ! !

8
Relevant Again
  • Alpha-1 blockers
  • 4 drugs marketed for prostatic outflow problems
  • Afluzosin (Uroxatral) new in US last year
  • Is alpha-1A blockade important for tolerance ?
  • Alpha-2 Agonists
  • Tizanidine (Zanaflex) for muscular spasm
  • Rebound can occur
  • Dexmedetomidine (Precedex) post-surgical
    sedation and analgesia
  • Are these drugs different from clonidine?

9
Dexmedetomidine (Precedex)
  • Primarily alpha-2 agonist (some alpha-1 at high
    doses)
  • ? Alpha-2A specificity
  • Post-surgical sedation and anesthesia,
  • Supresses sympathetic stimulation
  • Sedating without suppressing respiratory drive
  • Some analgesia
  • Pharmacokinetics
  • Terminal T1/2 is 2h
  • Glucuronidation
  • Rebound ?

10
Finally, a Partial Agonist
  • Aripirazole (Abilify)
  • FDA approved 2002
  • Pharmacodynamics
  • Partial agonist D2 and 5-HT1A receptors
  • Antagonist at 5-HT2A receptors
  • Clinically Effective
  • Less EPS (extrapyramidal side effects)
  • Monthly cost 300-600

11
Key Brain Dopamine Sites
Mesocortical Nigrostriatal
(EPS) Tubero- Infundibular (Prolactin)
Mesolimbic (Psych Sx)
AN
VTA
SN
12
Sites of Anti-Psychotic Action
Dopamine Mesolimbic Neuron
X
DA
D2
X
5-HT2A
Atypical Antipsychotics
5-HT
13
D2 Receptor Interactions
14
Real Receptor Interactions
Dopamine
100
Max. DA response
50
0
10-10 10-9 10-8
10-7 10-6 10-5
Drug
Chinese hamster ovary D2L cells exposed to 10 mM
EEDQ
15
Moving Targets
  • Lipid Lowering How much is enough?
  • Optimal LDL
  • How hard to push depends on RF
  • With DM or CAD use statin even with optimal LDL
  • Estrogen Replacment Is it too risky?
  • Prempro (conj. Estrogen/progestin)
  • More breast Ca
  • More cardiovascular events
  • Better ways to protect heart and bones in
    post-menopausal woman
  • But what to do about hot flashes ?

16
Summary
  • You cant quit learning
  • We cant teach you everything
  • Sometimes we dont even know what to teach
  • Be humble about how much you know
  • We dont know everything
  • Always ask questions
  • Everyone should be from Missouri
  • Make us proud
Write a Comment
User Comments (0)
About PowerShow.com